secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001326110-25-000069
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

ImmunityBio Reports Q1 2025 Net Product Revenue of $16.5M, Up 129% from Q4 2024
-------------------------------------------------------------------------------

- Net product revenue for Q1 2025 reached $16.5 million, a 129% increase over $7.2 million in Q4 2024.
- ANKTIVA unit sales volume grew 150% in Q1 2025 compared to Q4 2024, with March volume up 69% over February.
- Nearly 200 urology practices are registering for ImmunityBio's recombinant BCG Expanded Access Program (EAP).
- Positive long-term results from the QUILT 3.032 study showed highest cystectomy avoidance in NMIBC space.
- ImmunityBio completed a $75 million equity financing in April 2025 to support operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611025000069/0001326110-25-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611025000069/ibrx-20250512.htm
  HTML page:      https://secwatch.observer/filing/0001326110-25-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer